Astrana Health (ASTH) Stock Price, News & Analysis

Company Overview

Astrana Health (NASDAQ:ASTH) is a provider of comprehensive medical asset management solutions and services designed to support healthcare providers across the United States and Canada. The company partners with hospitals, health systems, alternate-site providers, imaging centers and laboratories to optimize equipment lifecycle management, ensuring that critical medical devices are available, functioning safely and compliant with industry standards.

The firm’s offerings span equipment acquisition planning, preventive maintenance, calibration, field-based repairs and emergency on-demand services. Astrana Health also maintains an extensive rental fleet of capital medical devices, enabling organizations to meet temporary capacity demands or bridge equipment downtime. Through its nationwide network of service technicians and strategically located distribution centers, the company delivers fast response times and ensures consistent parts availability.

Founded under the name Agiliti and publicly listed in 2018, the company rebranded as Astrana Health in 2023 to reflect its expanded focus on data-driven technology and compliance solutions. Headquartered in Charlotte, North Carolina, Astrana Health is led by President and Chief Executive Officer Athman Bylund, whose leadership has guided the organization through strategic acquisitions and growth initiatives aimed at broadening its service footprint and platform capabilities.

At the core of Astrana Health’s value proposition is its proprietary technology platform, which provides clients with real-time visibility into asset utilization, maintenance schedules and regulatory compliance status. By integrating operational data and analytics, the company helps healthcare organizations reduce equipment downtime, streamline workflows and mitigate risk. With a commitment to quality and patient safety, Astrana Health continues to expand its service network and enhance its technology solutions to meet the evolving needs of the healthcare industry.

Key Stats

• Today's Range: $24.64 to $25.50
• 50-Day Range: $24.00 to $33.44
• 52-Week Range: $23.12 to $63.20
• Volume: 310,514 shs
• Average Volume: 296,846 shs
• Market Capitalization: $1.40 billion
• P/E Ratio: 34.58
• Dividend Yield: N/A
• Price Target: $53.29
• Consensus Rating: Moderate Buy

Astrana Health Stock Analysis - MarketRank™

Astrana Health scored higher than 79% of companies evaluated by MarketBeat, and ranked 185th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Astrana Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Astrana Health has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 22.61%

Earnings Growth

Earnings for Astrana Health are expected to grow by 22.61% in the coming year, from $1.15 to $1.41 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Astrana Health is 34.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Astrana Health is 34.58, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.05.

Price to Earnings Growth Ratio

Astrana Health has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Astrana Health has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.85% of the float of Astrana Health has been sold short.

Short Interest Ratio / Days to Cover

Astrana Health has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Astrana Health has recently decreased by 2.72%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Astrana Health does not currently pay a dividend.

Dividend Growth

Astrana Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.85% of the float of Astrana Health has been sold short.

Short Interest Ratio / Days to Cover

Astrana Health has a short interest ratio ("days to cover") of 5.2.

Change versus previous month

Short interest in Astrana Health has recently decreased by 2.72%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.09

News Sentiment

Astrana Health has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Astrana Health this week, compared to 5 articles on an average week.

Search Interest

6 people have searched for ASTH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Astrana Health to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Astrana Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.00% of the stock of Astrana Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.77% of the stock of Astrana Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ASTH Stock Analysis - Frequently Asked Questions

How have ASTH shares performed this year?

Astrana Health's stock was trading at $31.53 on January 1st, 2025. Since then, ASTH shares have decreased by 21.0% and is now trading at $24.90.

How were Astrana Health's earnings last quarter?

Astrana Health, Inc. (NASDAQ:ASTH) issued its quarterly earnings results on Thursday, May, 8th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.23 by $0.09. The business's revenue for the quarter was up 53.4% on a year-over-year basis.
Read the conference call transcript.

Who are Astrana Health's major shareholders?

Astrana Health's top institutional investors include Westmount Partners LLC (0.15%).

How do I buy shares of Astrana Health?

Shares of ASTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Astrana Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Astrana Health investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ASTH
• Previous Symbol: NASDAQ:ASTH
• CIK: 1083446
• Web: www.apollomed.net
• Phone: 626-282-0288
• Fax: 818-839-5190
• Employees: 1,900
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Astrana Health: $53.29
• High Price Target: $70.00
• Low Price Target: $36.00
• Potential Upside/Downside: +114.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.72
• Trailing P/E Ratio: 34.58
• Forward P/E Ratio: 21.65
• P/E Growth: 0.94
• Net Income: $43.15 million
• Net Margins: 1.56%
• Pretax Margin: 2.95%
• Return on Equity: 4.90%
• Return on Assets: 2.68%

Debt

• Debt-to-Equity Ratio: 0.54
• Current Ratio: 1.70
• Quick Ratio: 1.70

Sales & Book Value

• Annual Sales: $2.03 billion
• Price / Sales: 0.69
• Cash Flow: $1.44 per share
• Price / Cash Flow: 17.25
• Book Value: $14.59 per share
• Price / Book: 1.71

Miscellaneous

• Outstanding Shares: 56,060,000
• Free Float: 44,850,000
• Market Cap: $1.40 billion
• Optionable: Optionable
• Beta: 0.84